Dren Bio announces a $60M Series A financing
Retrieved on:
Friday, October 16, 2020
Oncology, Professional services, Health, Genetics, Venture capital, Pharmaceutical, Biotechnology, Dren, Articles, High Performance Computing Modernization Program, Protein aggregation, Biotechnology, Protein, Branches of biology, Health, Dren Bio, SR One, Taiho Ventures, 8VC, BVF Partners L.P., HBM Healthcare Investments, Mission BioCapital, Alexandria Venture Investments
Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round.
Key Points:
- Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round.
- Dren previously closed a $6 million Seed Financing in 2019 led by 8VC with participation by Mission BioCapital and prominent industry veterans.
- The goal of our Series A financing is to bring two drug candidates to the clinic.
- Dren Bio is a San Carlos, CA based biotechnology company developing powerful protein engineering technologies to deplete cells, protein aggregates and other disease-causing agents.